Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | USP1 | O94782 | 1/20 | 0.31 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13315479 | 0.84 | TLR9 (0.33) | LMNARPS6KA3CYP3A4CYP2A6CYP2B6 | |
| SCHEMBL29047862 | 0.83 | CYP3A4 (0.33) | CYP3A4CYP2A6CYP2B6CYP2C19 | |
| SCHEMBL17586760 | 0.81 | RPS6KA3 (0.33) | RPS6KA3P2RX3P2RX2CA1CA2 | |
| SCHEMBL21736900 | 0.79 | RPS6KA3 (0.36) | RPS6KA3P2RX3P2RX2CA1CA2 | |
| SCHEMBL20844146 | 0.78 | AAK1 (0.34) | LMNARPS6KA3TLR9TLR8TLR7 | |
| SCHEMBL24595050 | 0.77 | GABRA1 (0.37) | LMNARPS6KA3TLR9TLR8TLR7 | |
| SCHEMBL20001452 | 0.77 | RPS6KA3 (0.35) | RPS6KA3P2RX3P2RX2CA1CA2 | |
| SCHEMBL2611021 | 0.76 | UHRF1 (0.50) | LMNACYP2A6ACHEP2RX3P2RX2 | |
| SCHEMBL13086010 | 0.75 | — | — | |
| SCHEMBL21503593 | 0.75 | NOS3 (0.36) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365557-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-11802126-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2023-10-31 | — | — | US | disclosed |
| US-20230295145-A1 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | GENENTECH INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295145-A1 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | GENENTECH INC (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023122298-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-4079724-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022115879-A1 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | GENENTECH, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20210347774-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2021-11-11 | — | — | US | disclosed |
| US-10968188-B2 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2021-04-06 | — | — | US | disclosed |
| US-20200270246-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2020-08-27 | — | — | US | disclosed |
| US-20200270222-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2020-08-27 | — | — | US | disclosed |
| US-10669246-B2 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2020-06-02 | — | — | US | disclosed |
| US-20190100500-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2019-04-04 | — | — | US | disclosed |
| US-9579319-B2 | Heterocyclic compounds as hedgehog signaling pathway inhibitors | REDX PHARMA PLC (GB) | 2017-02-28 | — | — | US | disclosed |
| US-20160113928-A1 | HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS | REDX PHARMA PLC (GB) | 2016-04-28 | — | — | US | disclosed |
| US-7727998-B2 | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365557-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | LMNA 1809/4885RPS6KA3 1910/4885CYP3A4 2447/4885 |
| US-20230295145-A1 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | DPYD, TP53, GLS | LMNA 2962/4885RPS6KA3 1062/4885CYP3A4 1439/4885 |
| US-20160113928-A1 | HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS | SMO, SHH, GLI1 | LMNA 4803/4885RPS6KA3 1225/4885CYP3A4 3223/4885 |
| US-20190100500-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | ABL2, ABL1, MAPT | LMNA 2738/4885RPS6KA3 701/4885CYP3A4 4781/4885 |
| US-11802126-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | SMN1; SMN2, SNCA, HTT | LMNA 1809/4885RPS6KA3 1910/4885CYP3A4 2447/4885 |
| US-10669246-B2 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | ABL2, ABL1, MAPT | LMNA 2738/4885RPS6KA3 701/4885CYP3A4 4781/4885 |
| US-10968188-B2 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | ABL2, ABL1, MAPT | LMNA 2738/4885RPS6KA3 701/4885CYP3A4 4781/4885 |
| US-20200270246-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | LMNA 1809/4885RPS6KA3 1910/4885CYP3A4 2447/4885 |
| US-20210347774-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | LMNA 1809/4885RPS6KA3 1910/4885CYP3A4 2447/4885 |
| US-20200270222-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | ABL2, ABL1, MAPT | LMNA 2738/4885RPS6KA3 701/4885CYP3A4 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.